These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10147025)

  • 1. Should indirect costs and benefits be included?
    Henry DA
    Pharmacoeconomics; 1992 Jun; 1(6):462. PubMed ID: 10147025
    [No Abstract]   [Full Text] [Related]  

  • 2. Functional dyspepsia impacts absenteeism and direct and indirect costs.
    Brook RA; Kleinman NL; Choung RS; Melkonian AK; Smeeding JE; Talley NJ
    Clin Gastroenterol Hepatol; 2010 Jun; 8(6):498-503. PubMed ID: 20304102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic costs of functional dyspepsia.
    Nyrén O; Lindberg G; Lindström E; Marké LA ; Seensalu R
    Pharmacoeconomics; 1992 May; 1(5):312-24. PubMed ID: 10146996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden.
    Agréus L; Borgquist L
    Pharmacoeconomics; 2002; 20(5):347-55. PubMed ID: 11994044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy.
    Walan A; Wahlqvist P
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S79-88. PubMed ID: 10379474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost of lost productivity in pharmacoeconomics analysis. Part II. Survey in the expert group].
    Wrona W; Hermanowski T; Jakubczyk M; Golicki D; Czech M; Niewada M; Kolasa K
    Przegl Epidemiol; 2011; 65(1):153-7. PubMed ID: 21735853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonulcer dyspepsia and proton pump inhibitors.
    Waldum HL; Martinsen TC; Brenna E
    Gastroenterology; 2005 Mar; 128(3):805; author reply 805-6. PubMed ID: 15765429
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of organic and functional dyspepsia on work productivity: the HEROES-DIP study.
    Sander GB; Mazzoleni LE; Francesconi CF; Balbinotto G; Mazzoleni F; Wortmann AC; Cardoso Ide Q; Klamt AL; Milbradt TC;
    Value Health; 2011; 14(5 Suppl 1):S126-9. PubMed ID: 21839884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Societal burden of cluster headache in the United States: a descriptive economic analysis.
    Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
    J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do cost-effectiveness analyses cause you dyspepsia?
    Ganiats TG
    J Fam Pract; 1997 Jun; 44(6):541-2. PubMed ID: 9191625
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
    De Francesco V; Della Valle N; Stoppino V; Amoruso A; Muscatiello N; Panella C; Ierardi E
    Aliment Pharmacol Ther; 2004 May; 19(9):993-8. PubMed ID: 15113366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Work productivity improvement after acid suppression in patients with uninvestigated dyspepsia.
    Bytzer P; Langkilde LK; Christensen E; Meineche-Schmidt V
    Dan Med J; 2012 Jul; 59(7):A4461. PubMed ID: 22759841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Introduction to the theory of pharmaco-economics].
    Kurz X; Dresse A
    Rev Med Liege; 1998 May; 53(5):230-5. PubMed ID: 9689873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 15. NICE issues guidance for heartburn and indigestion.
    Ferriman A
    BMJ; 2000 Jul; 321(7255):197. PubMed ID: 10903645
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole--results from the STARS II study.
    van Zanten SV; Wahlqvist P; Talley NJ; Halling K; Vakil N; Lauritsen K; Flook N; Persson T; Bolling-Sternevald E;
    Aliment Pharmacol Ther; 2011 Oct; 34(7):714-23. PubMed ID: 21848799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia.
    Kearney DJ; Liu CF; Crump C; Brousal A
    Am J Gastroenterol; 2003 Sep; 98(9):1952-62. PubMed ID: 14499771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost analysis of gastro-oesophageal reflux disease and dyspepsia in Iran.
    Rezailashkajani M; Roshandel D; Shafaee S; Zali MR
    Dig Liver Dis; 2008 Jun; 40(6):412-7. PubMed ID: 18342588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacoeconomics. Potent drugs, diseases are costly].
    Flaten O
    Tidsskr Nor Laegeforen; 1994 Apr; 114(11):1345-6. PubMed ID: 8079219
    [No Abstract]   [Full Text] [Related]  

  • 20. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece.
    Souliotis K; Kousoulakou H; Hillas G; Tzanakis N; Toumbis M; Vassilakopoulos T
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1395-1400. PubMed ID: 28546747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.